Published in Case Rep Oncol on April 25, 2009
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer (2004) 3.03
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol (2002) 2.86
Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol (2001) 2.21
Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res (2000) 2.16
Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci U S A (1990) 2.03
Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci U S A (1992) 1.96
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst (1995) 1.91
Androgen axis in prostate cancer. J Cell Biochem (2006) 1.48
Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem (2004) 1.34
The androgen receptor: a potential target for therapy of prostate cancer. Steroids (2004) 1.10
Clinical review 134: The endocrinology of prostate cancer. J Clin Endocrinol Metab (2001) 1.10
Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology (2003) 0.98
Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol Cancer Ther (2006) 0.95
Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis (2004) 0.90
The novel estrogen 17alpha-20Z-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10),20-tetraene-3,17beta-diol induces apoptosis in prostate cancer cell lines at nanomolar concentrations in vitro. Mol Cancer Ther (2004) 0.87
Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer. Prostate (2008) 0.85
Co-administration of finasteride and the pure anti-oestrogen ICI 182,780 act synergistically in modulating the IGF system in rat prostate. J Endocrinol (2001) 0.81
Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents. Cancer Chemother Pharmacol (2001) 0.78
Melanoma: from darkness to promise. Am J Clin Oncol (2011) 0.87
Langerhans cell histiocytosis. Clin Transl Oncol (2008) 0.85
Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients. Am J Clin Oncol (2011) 0.81
Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate. Case Rep Oncol (2009) 0.77
Old and new insights in the treatment of thyroid carcinoma. J Thyroid Res (2010) 0.77
Young male patient with bilateral synchronous testicular germ cell tumour. Considerations for partial orchiectomy. Clin Transl Oncol (2008) 0.75
Phase II trial of concomitant neoadjuvant chemotherapy with oxaliplatin and capecitabine and intensity-modulated radiotherapy (IMRT) in rectal cancer. J Gastrointest Cancer (2012) 0.75